Video

Dr. Ocean on the Development of Nanoliposomal Irinotecan in Metastatic Pancreatic Cancer

Allyson Ocean, ​MD, discusses the need for additional second-line therapies in metastatic pancreatic cancer. 

Allyson Ocean, ​MD, an associate attending physician, NewYork-Presbyterian Hospital, and associate professor of clinical medicine at Weill Cornell Medicine, discusses the need for additional second-line therapies in metastatic pancreatic cancer. 

FOLFIRINOX and the combination of gemcitabine plus nab-paclitaxel (Abraxane) have demonstrated survival advantages in the first-line setting for patients with metastatic pancreatic cancer, says Ocean. However, ​these patients often progress ​and require second-line therapy. 

Notably, the unmet need in this space led to the development of nanoliposomal irinotecan (Onivyde), a unique compound that can induce a prolonged response and better cell kill, Ocean concludes. 

Related Videos
Anthony M. Hunter, MD
Amrita Krishnan, MD, City of Hope
Jonathan C. Trent, MD, PhD
Alexey Danilov, MD, PhD
Tycel Phillips, MD
Lori Wirth, MD
Moritz Fürstenau MD, Division of Haematology, Immunology, Infectiology, Intensive Care, and Oncology, University of Cologne
Aaron Gerds, MD
Tilak Sundaresan, MD
5 KOLs are featured in this panel.